Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Inova Health Care Services
With
Brown University
Tufts University
George Washington University
Pulmonary Arterial Hypertension (PAH) is associated with fluid retention. Currently, the treatment paradigm for newly diagnosed PAH patients includes evaluation for Obstructive Sleep Apnea (OSA). The investigators propose that untreated or sub-optimally managed PAH patients have significant fluid retention which redistributes to the upper body during sleep and exacerbates or even mimics OSA. The investigators hypothesize that treatment of PAH patients with vasodilators and diuretics to optimize fluid balance will attenuate or even resolve OSA prior to the initiation of specific therapy for OSA (CPAP).
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
• Diagnosis of Group 1 PAH
* Either lack of treatment for PAH or sub-optimally treated PAH as defined by NYHA FC 3 or 4
* Age 18 or older
* Ability to give consent
* Ability to undergo overnight polysomnogram
* Previously diagnosed OSA not on therapy
You may not be if
Age younger than 18
Pregnancy
Previously diagnosed OSA and receiving therapy
Inability to undergo overnight polysomnography in laboratory
Clareo Health | Obstructive Sleep Apnea (OSA) in Pulmonary Arterial Hypertension (PAH)
